Naltrexone Purification Using Cyclopentyl Methyl Ether
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for the purification and crystallization of naltrexone base using ethers result in poor solubility, low yields, and insufficient purity, with most patents lacking detailed data on product purity or content.
Innovation Solution
The use of cyclopentyl methyl ether (CPME) for crystallization and extraction of naltrexone base, which offers high purity and yield, allowing for repeated crystallization to achieve purity above 98% and enabling the isolation of naltrexone from reaction mixtures with ease, even at elevated temperatures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional solvents (water, acetone, chlorinated solvents) are used for naltrexone crystallization, then the process is well-established, but the purity and yield are insufficient (below 98% purity)
Solution Approach 1:
The patent changes the fundamental parameter of solvent type from conventional solvents (water, acetone, chlorinated solvents) to cyclic ethers (2-methyltetrahydrofuran, 2-ethyl-2-methyl-1,3-dioxolane). This parameter change enables simultaneous achievement of high purity (above 98%) and high yield (above 80%), resolving the contradiction between manufacturing precision and productivity that plagues conventional methods.
2Manufacturing precision
If multiple crystallization steps are performed to achieve high purity, then purity increases, but the process time and complexity increase
Solution Approach 1:
By changing the solvent parameter to cyclic ethers, the patent achieves high purity (above 98%) in a single crystallization step, eliminating the need for multiple sequential crystallizations required by conventional methods. This dramatically reduces process time while maintaining high manufacturing precision.
3Ease of manufacture
If naltrexone is isolated from reaction mixture by extraction, then the isolation is achieved, but additional purification steps are required and water content increases
Solution Approach 1:
The patent changes the solvent parameter to cyclic ethers which provide both excellent extraction capabilities and inherent drying properties. The isolation process becomes easier while simultaneously achieving high purity (above 98%) and low water content (below 0.5%), eliminating the need for additional purification steps required after conventional extraction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cyclopentyl methyl ether provides a solvent system that achieves high purity (above 98%) and yield (over 80%) for naltrexone base, suitable for both initial purification and recrystallization, with the added advantage of low water content and environmental acceptability, making it suitable for industrial use.
Implementation Method 1
naltrexone base has good solubility in cyclopentyl methyl ether already at slightly elevated temperatures (diluted solutions) or at elevated temperatures (concentrated solutions)
Implementation Method 2
use of cyclopentyl methyl ether of structure 2 (CPME) for crystallization of naltrexone overcomes the prior art and leads to the yield of white to light beige product with high purity and content above 98% (HPLC)
Implementation Method 3
following effective removal of water with azeotropic distillation of the mixture of cyclopentyl methyl ether-water
Data Source
AI summary
The invention describes a method for purification of naltrexone base from reaction mixtures concentrated by evaporation and/or from mixtures containing naltrexone in the presence of other organic or inorganic substances by trituration and/or extraction and crystallization from cyclopentyl methyl ether (CPME), optionally from a mixture of cyclopentyl methyl ether and another organic solvent. Naltrexone of high purity is obtained by this method and can be used in a parenteral dosage form.